OPTILAST

This brand name is authorized in Ireland, Israel, United Kingdom, South Africa

Active ingredients

The drug OPTILAST contains one active pharmaceutical ingredient (API):

1 Azelastine UNII 0L591QR10I - AZELASTINE HYDROCHLORIDE

Azelastine, a phthalazinone derivative is classified as a potent long-acting anti-allergic compound with selective H1 antagonist properties. An additional anti-inflammatory effect could be detected after topical ocular administration. Data from in vivo (pre-clinical) and in vitro studies show that azelastine inhibits the synthesis or release of the chemical mediators known to be involved in early and late stage allergic reactions e.g. leukotriene, histamine, PAF and serotonin. Read about Azelastine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
OPTILAST Eye drops	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
S01GX07	Azelastine	S Sensory organs → S01 Ophthalmologicals → S01G Decongestants and antiallergics → S01GX Other antiallergics
Discover more medicines within S01GX07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 48911
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 4556
Country: ZA	Health Products Regulatory Authority	Identifier(s): 36/15.4/0011